Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152405 | 1.00 | PRKCA (0.40) | PRKCAMMP12CSNK2A1KDM4EUSP2 | |
| SCHEMBL4140592 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL4140597 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1 | |
| SCHEMBL4152338 | 0.92 | PRKCA (0.33) | PRKCAMMP12KDM4EUSP2ALDH1A1 | |
| SCHEMBL4152334 | 0.92 | PRKCA (0.33) | PRKCAMMP12KDM4EUSP2ALDH1A1 | |
| SCHEMBL4152231 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1ESR1 | |
| SCHEMBL4152229 | 0.92 | PRKCA (0.40) | PRKCAMMP12CSNK2A1ESR1 | |
| SCHEMBL4149639 | 0.90 | PRKCA (0.39) | PRKCAMMP12ESR1 | |
| SCHEMBL4152682 | 0.90 | PRKCA (0.39) | PRKCAMMP12ESR1 | |
| SCHEMBL4156042 | 0.89 | PRKCA (0.38) | PRKCAMMP12KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | PRKCA 4320/4885MMP12 3563/4885CSNK2A1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.